Study of the effect of Lactobacillus FSCDJY67L3 on eradication: a double-blind randomized controlled clinical trial.

UNLABELLED

() is a gram-negative bacterium exhibiting high pathogenicity. Traditional antibiotic treatments are considered ineffective as the resistance has increased. Recently, a quadruple therapy strategy of probiotics and antibiotics to eliminate was proposed. Probiotics play a therapeutic role as supplements in this process. The present research screened a probiotic strain ( FSCDJY67L3) that co-aggregates strongly with . FSCDJY67L3 was demonstrated to significantly reduce load (C breath test) in clinical trials with positive patients. The Gastrointestinal Symptom Rating Scale (GSRS) score decreased, indicating improvement in the gastrointestinal discomfort of patients. Furthermore, FSCDJY67L3 showed no change in the structure of the intestinal flora of patients. Routine blood indices and blood biochemical indices related to liver and kidney function were also not affected in the patients. Therefore, FSCDJY67L3 may be used clinically as a supplement for the treatment of .

CLINICAL TRIAL REGISTRATION

https://www.chictr.org.cn/, Chinese Clinical Trial Registry (ChiCTR2100053710).

Copyright © 2023 Hong, Wang, Zhang, Liu and Liu.